238 Main Street
9th Floor
Cambridge, MA 02142
United States
857 327 8775
https://www.beamtx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 394
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. John M. Evans M.B.A. | CEO & Director | 1.02M | 1.62M | 1978 |
Dr. Giuseppe Ciaramella Ph.D. | Pres & Chief Scientific Officer | 890.79k | 14.85M | 1969 |
Ms. Terry-Ann Burrell M.B.A. | CFO & Treasurer | 687.52k | 9.18M | 1977 |
Dr. Feng Zhang Ph.D. | Co-Founder | N/A | N/A | N/A |
Dr. David R. Liu Ph.D. | Co-Founder | N/A | N/A | N/A |
Dr. J. Keith Joung M.D., Ph.D. | Co-Founder | N/A | N/A | N/A |
Dr. Nicole Gaudelli Ph.D. | Co-Founder | N/A | N/A | N/A |
Dr. Alexis Komor Ph.D. | Co-Founder | N/A | N/A | N/A |
Ms. Suzanne Fleming | Chief Accounting Officer | N/A | N/A | 1961 |
Mr. Brian Riley | Sr. VP of Technical Operations | N/A | N/A | 1977 |
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Beam Therapeutics Inc.’s ISS governance QualityScore as of 1 June 2022 is 7. The pillar scores are Audit: 7; Board: 8; Shareholder rights: 6; Compensation: 8.